对伴高凝状态的恶性肿瘤患者进行抗凝联合化疗的临床观察(1)
 |
| 第1页 |
参见附件(1473KB，2页)。
[摘要] 目的：观察伴高凝状态的恶性肿瘤患者进行抗凝联合化疗的临床疗效。方法：对44例伴高凝状态恶性肿瘤患者进行抗凝加化疗，设为治疗组，给予一线标准方案化疗，同时给予低分子肝素钙6 000 U并伴随化疗，1次/d，皮下注射，阿司匹林100 mg po，1次/d，21～28 d为1个周期，4个周期为1个疗程。对照组患者单独采用一线标准方案化疗。结果：治疗组和对照组有效率分别为22.7%和18.2%，两组比较，差异无统计学意义(P>0.05)；两组中位生存期(MST)分别为30.2个月和29.2个月，两组比较，差异无统计学意义(P>0.05)；治疗组和对照组KPS改善率分别为63.6%和36.4%，两组比较，差异有统计学意义(P<0.05)。两组毒性反应基本相同。结论：伴高凝状态恶性肿瘤患者进行化疗时加抗凝治疗，效果较好，值得临床使用。
[关键词] 恶性肿瘤；高凝状态；抗凝治疗；化疗
[中图分类号] R552[文献标识码]A [文章编号]1673-7210(2010)10(c)-028-02
Clinical observation of anticoagulation combined chemotherapy in the treatment of m alignant tumor patients with hypercoagulable state
YANG Yaokun, ZHANG Yuechen, WANG Jianming
(Department of Medical Oncology, the Second People′s Hospital of Fuxin City, Fuxin 123000, China)
[Abstract] Objective: To observe the clinical effect of anticoagulation combined chemotherapy in the treatment of m alignant tumor patients with hypercoagulable state. Methods: 44 m alignant tumor patients with hypercoagulable state were enrolled into the study. They were accepted the treatment of the first standard chemotherapy and anticoagulation. The treatment of anticoagulation included low-molecular-weight heparin calcium 6 000 U ih following the chemotherapy and asprin 100 mg po, qd, the treatment was repeated every 21-28 days. After 4 cycles of chemotherapy, the efficacy and toxicity were evaluated. The other 44 patients of the control group were only accepted the first standard chemotherapy. Results: The efficacious rates were 22.7% (treatment group) and 18.2% (control group), there was no significant difference (P>0.05). The median survival time (MST) of the two groups were 30.2 months and 29.2 months, there was no significant difference (P>0.05). The KPS improvement rate of the two groups were 63.6% and 36.4%, there was a significant difference (P<0.05). The toxicity of the two groups were almost close. Conclusion: It′s benefit from anticoagulation combined chemotherapy for the m alignant tumor patients with hypercoagulable state. It′s worthy of promotion ......
您现在查看是摘要介绍页，详见PDF附件(1473KB，2页)。